1. Safety and Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists: Pilot Implementation of a Near‐Real‐Time Monitoring Program in Italy
by Flavia Mayer, Ursula Kirchmayer, Paola Coletta, Nera Agabiti, Valeria Belleudi, Giovanna Cappai, Mirko Di Martino, Sebastian Schneeweiss, Marina Davoli, and Elisabetta Patorno
J Am Heart Assoc
Volume 7(6):e008034
March 10, 2018
© 2018 Flavia Mayer et al.

2. Cohort selection.
Cohort selection. AF indicates atrial fibrillation; DOAC, direct oral anticoagulants; ICD‐9‐CM, the International Classification of Diseases, 9th Revision, Clinical Modification; PS, propensity score; VKA, vitamin K antagonists.
Flavia Mayer et al. J Am Heart Assoc 2018;7:e008034
© 2018 Flavia Mayer et al.

3. Mortality—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists.
Mortality—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists.
Flavia Mayer et al. J Am Heart Assoc 2018;7:e008034
© 2018 Flavia Mayer et al.

4. Cardiovascular mortality—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists.
Cardiovascular mortality—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists.
Flavia Mayer et al. J Am Heart Assoc 2018;7:e008034
© 2018 Flavia Mayer et al.

5. Acute myocardial infarction—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists.
Acute myocardial infarction—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists.
Flavia Mayer et al. J Am Heart Assoc 2018;7:e008034
© 2018 Flavia Mayer et al.

6. Ischemic stroke—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists.
Ischemic stroke—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists.
Flavia Mayer et al. J Am Heart Assoc 2018;7:e008034
© 2018 Flavia Mayer et al.

7. Hemorrhagic stroke—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists.
Hemorrhagic stroke—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists.
Flavia Mayer et al. J Am Heart Assoc 2018;7:e008034
© 2018 Flavia Mayer et al.

8. Gastrointestinal bleeding—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists.
Gastrointestinal bleeding—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists.
Flavia Mayer et al. J Am Heart Assoc 2018;7:e008034
© 2018 Flavia Mayer et al.